Clinical trial
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
NCT02631044 is registered in ClinicalTrials.gov with Juno Therapeutics, a Subsidiary of Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
- Lead sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 6, 2016
- Completion date
- May 16, 2024
- Enrollment
- 387 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse large b cell lymphoma, follicular lymphoma, mantle-cell lymphoma, non-hodgkin lymphoma, primary mediastinal b-cell lymphoma